In contrast, Elisa Giannetta and her team argue that the new immunochemiluminometric assay has improved the reliability and sensitivity of calcitonin and that its measurement should be systematic in all nodular thyroid diseases because it allows for early diagnosis of a potentially more aggressive tumor and improves the sensitivity of cytology (which is less than 50% for MTC) [11]. This evidence concerns the gene CALCA and neoplasm.